Currently, there are 1.46B common shares owned by the public and among those 1.46B shares have been available to trade.
Insiders at the company have transacted a total of 106 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 58 of these insider trades were purchases, accounting for 759,377 shares. Insider sales of the common stock occurred on 48 occasions, with total insider shares sold totaling 1,157,189 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The company’s stock has a 5-day price change of 1.89% and 21.13% over the past three months. BSX shares are trading 14.55% year to date (YTD), with the 12-month market performance up to 42.47% higher. It has a 12-month low price of $45.92 and touched a high of $66.86 over the same period. BSX has an average intraday trading volume of 6.41 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 4.18%, 10.69%, and 21.85% respectively.
Institutional ownership of Boston Scientific Corp. (NYSE: BSX) shares accounts for 94.08% of the company’s 1.46B shares outstanding.
It has a market capitalization of $97.01B and a beta (3y monthly) value of 0.78. The stock’s trailing 12-month PE ratio is 61.87, while the earnings-per-share (ttm) stands at $1.07. The company has a PEG of 5.14 and a Quick Ratio of 0.90 with the debt-to-equity ratio at 0.49. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.40% over the week and 1.39% over the month.
Analysts forecast that Boston Scientific Corp. (BSX) will achieve an EPS of $0.51 for the current quarter, $0.56 for the next quarter and $2.55 for 2025. The lowest estimate earnings-per-share for the quarter is $0.5 while analysts give the company a high EPS estimate of $0.52. Comparatively, EPS for the current quarter was $0.47 a year ago. Earnings per share for the fiscal year are expected to increase by 10.00%, and 13.19% over the next financial year. EPS should grow at an annualized rate of 12.04% over the next five years, compared to -2.05% over the past 5-year period.
Looking at the support for the BSX, a number of firms have released research notes about the stock. Mizuho stated their Buy rating for the stock in a research note on February 01, 2024, with the firm’s price target at $65-$80. Robert W. Baird coverage for the Boston Scientific Corp. (BSX) stock in a research note released on July 19, 2023 offered a Outperform rating with a price target of $59. CL King was of a view on June 30, 2023 that the stock is Buy, while Morgan Stanley gave the stock Overweight rating on May 30, 2023, issuing a price target of $58. UBS on their part issued Buy rating on March 29, 2023.
